[go: up one dir, main page]

BR0212019A - Dosage forms, methods for treating pain, methods of preparing a dosage form and methods for preventing abuse of a dosage form. - Google Patents

Dosage forms, methods for treating pain, methods of preparing a dosage form and methods for preventing abuse of a dosage form.

Info

Publication number
BR0212019A
BR0212019A BR0212019-4A BR0212019A BR0212019A BR 0212019 A BR0212019 A BR 0212019A BR 0212019 A BR0212019 A BR 0212019A BR 0212019 A BR0212019 A BR 0212019A
Authority
BR
Brazil
Prior art keywords
methods
dosage form
dosage
preparing
dosage forms
Prior art date
Application number
BR0212019-4A
Other languages
Portuguese (pt)
Inventor
Christopher Breder
Benjamin Oshlack
Richard Sackler
Curtis Wright
Robert Colucci
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BR0212019A publication Critical patent/BR0212019A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMAS DE DOSAGEM, MéTODOS PARA O TRATAMENTO DA DOR, MéTODOS DE PREPARAçãO DE UMA FORMA DE DOSAGEM E MéTODOS PARA IMPEDIR O ABUSO DE UMA FORMA DE DOSAGEM". Trata-se de métodos e composições para impedir o abuso de formas de dosagem de um analgésico de opióide e um antagonista de opióide que inclui pelo menos um agente aversivo em uma quantidade eficaz para impedir que um usuário em abuso administre uma forma alterada da dita forma de dosagem intravenosamente, intranasalmente, e/ou oralmente."DOSAGE FORMS, METHODS FOR THE TREATMENT OF PAIN, METHODS FOR PREPARING A DOSAGE FORM AND METHODS TO PREVENT ABUSE OF A DOSAGE FORM". These are methods and compositions for preventing abuse of dosage forms of an opioid analgesic and an opioid antagonist that includes at least one aversive agent in an amount effective to prevent an abused user from administering an altered form of said form. intravenously, intranasally, and / or orally.

BR0212019-4A 2001-08-06 2002-08-06 Dosage forms, methods for treating pain, methods of preparing a dosage form and methods for preventing abuse of a dosage form. BR0212019A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31051601P 2001-08-06 2001-08-06
US31053701P 2001-08-06 2001-08-06
US31051501P 2001-08-06 2001-08-06
PCT/US2002/024934 WO2003013479A1 (en) 2001-08-06 2002-08-06 Compositions and methods to prevent abuse of opioids

Publications (1)

Publication Number Publication Date
BR0212019A true BR0212019A (en) 2005-08-09

Family

ID=27405462

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212019-4A BR0212019A (en) 2001-08-06 2002-08-06 Dosage forms, methods for treating pain, methods of preparing a dosage form and methods for preventing abuse of a dosage form.

Country Status (10)

Country Link
EP (1) EP1414418A1 (en)
JP (1) JP2005501067A (en)
KR (1) KR20040060917A (en)
AU (1) AU2002319774B2 (en)
BR (1) BR0212019A (en)
CA (1) CA2456322A1 (en)
DE (1) DE20220910U1 (en)
HU (1) HUP0401195A3 (en)
MX (1) MXPA04001208A (en)
WO (1) WO2003013479A1 (en)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2412409T3 (en) 1997-12-22 2013-07-11 Euro-Celtique S.A. Pharmaceutical form for oral dosage comprising a combination of an opioid agonist and an opioid antagonist
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
DE60223254T2 (en) 2001-07-06 2008-08-14 Penwest Pharmaceuticals Co. DELAYED FORCULATING FORMULATIONS OF OXYMORPHONE
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003004031A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
EP1492511B3 (en) 2002-04-09 2012-05-02 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10250083A1 (en) * 2002-06-17 2003-12-24 Gruenenthal Gmbh Dosage form protected against abuse
PT1894562E (en) * 2002-08-15 2011-01-14 Euro Celtique Sa Pharmaceutical compositions comprising an opioid antagonist
DE10250088A1 (en) * 2002-10-25 2004-05-06 Grünenthal GmbH Dosage form protected against abuse
DE10250084A1 (en) * 2002-10-25 2004-05-06 Grünenthal GmbH Dosage form protected against abuse
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
EP1615625A4 (en) * 2003-04-21 2010-12-15 Euro Celtique Sa INVIOLABLE DOSAGE FORM CONTAINING CO-EXTRUDED PARTICLES OF REPELLENT AGENT AND METHOD OF MANUFACTURING THE SAME
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
MXPA05011557A (en) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Compositions for affecting weight loss.
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
CA2557839C (en) 2004-03-30 2011-05-10 Euro-Celtique S.A. Tamper resistant dosage form comprising an adsorbent and an adverse agent
DE102004019916A1 (en) * 2004-04-21 2005-11-17 Grünenthal GmbH Anti-abuse drug-containing patch
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
GEP20105052B (en) * 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
FR2889810A1 (en) * 2005-05-24 2007-02-23 Flamel Technologies Sa ORAL MEDICINAL FORM, MICROPARTICULAR, ANTI-MEASUREMENT
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
FR2883179B1 (en) 2005-03-18 2009-04-17 Ethypharm Sa COATED TABLET
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
JP5180092B2 (en) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド Compositions and methods for increasing insulin sensitivity
EP1810714A1 (en) * 2006-01-19 2007-07-25 Holger Lars Hermann Use of a combination of heroin and naloxon for drug substitution
ES2749800T3 (en) * 2006-06-05 2020-03-23 Nalpropion Pharmaceuticals Llc Naltrexone Sustained Release Formulation
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070286900A1 (en) * 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
AU2014200910B2 (en) * 2006-10-03 2017-02-09 Arbutus Biopharma Corporation Lipid containing formulations
MX343867B (en) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Methods for administering weight loss medications.
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
WO2008150526A1 (en) * 2007-06-04 2008-12-11 Shear/Kershman Laboratories, Inc. Tamper resistant lipid-based oral dosage form for opioid agonists
PL2187873T3 (en) 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
EP2219612A4 (en) 2007-12-17 2013-10-30 Paladin Labs Inc CONTROLLED RELEASE FORMULATION AVOIDING IMPROPER USES
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
RU2508092C2 (en) 2008-05-09 2014-02-27 Грюненталь Гмбх Method for preparing solid dosage form, particularly tablet for pharmaceutical application and method for preparing solid dosage form precursor, particularly tablet
MX2010012909A (en) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Methods for treating visceral fat conditions.
US8420700B1 (en) * 2008-06-04 2013-04-16 James M. Bausch Tamper resistant lipid-based oral dosage form for sympathomimetic amines
FR2938431B1 (en) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma NOVEL COMPOSITION BASED ON GAMMA-HYDROXYBUTYRIC ACID
CA2746888C (en) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
BRPI1006186A2 (en) 2009-03-10 2016-08-23 Euro Celtique Sa immediate release pharmaceutical compositions comprising oxycodone and naloxone
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
ES2534908T3 (en) 2009-07-22 2015-04-30 Grünenthal GmbH Hot melt extruded controlled release dosage form
PL2456424T3 (en) 2009-07-22 2013-12-31 Gruenenthal Gmbh Oxidation-stabilized tamper-resistant dosage form
FR2949062B1 (en) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma NEW PHARMACEUTICAL FORMULATIONS AGAINST MEASURING MEDICINES
FR2949061B1 (en) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma FLOATING MICROGRANULES
EP2523557B1 (en) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
MX344846B (en) 2010-05-10 2017-01-10 Euro-Celtique S A * COMBINATION OF ACTIVE LOADED GRANULES WITH ADDITIONAL ASSETS.
US9700508B2 (en) 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
PL2611425T3 (en) 2010-09-02 2014-09-30 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
PE20131102A1 (en) 2010-09-02 2013-10-12 Gruenenthal Chemie HANDLING RESISTANT DOSAGE FORM INCLUDING INORGANIC SALT
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
AU2012219322A1 (en) * 2011-02-17 2013-05-09 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
NO2736497T3 (en) 2011-07-29 2018-01-20
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
ES2436344B1 (en) * 2012-05-29 2014-08-07 Onedose Pharma, S.L. Pharmaceutical composition of diacetylmorphine and naloxone for oral administration
PL4104824T3 (en) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
JP6466417B2 (en) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング A tamper-resistant dosage form with a bimodal release profile
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
BR112016000194A8 (en) 2013-07-12 2019-12-31 Gruenenthal Gmbh tamper-resistant dosage form containing ethylene vinyl acetate polymer
JP2016525138A (en) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． Oxycodone and naloxone combination for use in the treatment of pain in patients suffering from diseases that cause pain and intestinal dysbiosis and / or diseases that increase the risk for intestinal bacterial transfer
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CN106572980A (en) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (en) 2014-05-26 2017-05-31 Грюненталь Гмбх DOSAGE FORM AS PARTICLE MULTIPLE, PROTECTED AGAINST CALLED DOSE RESET BY ETHANOL
US9132096B1 (en) * 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
MX2017013637A (en) 2015-04-24 2018-03-08 Gruenenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction.
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
EP3435984A4 (en) * 2016-03-31 2019-11-06 SpecGx LLC POSITIVE DOSAGE FORMS WITH EXTENDED RELEASE
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
AU2018390826B2 (en) 2017-12-20 2024-09-12 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
KR102140493B1 (en) * 2019-05-30 2020-08-03 충북대학교 산학협력단 Composition for preventing or treating of bone diseases comprising denatonium compound
CN115768270A (en) * 2020-07-01 2023-03-07 比利时胶囊公司 Dietary compositions and methods
JP2024115533A (en) * 2023-02-14 2024-08-26 沢井製薬株式会社 Coated granules, preparations containing coated granules, and methods for producing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations

Also Published As

Publication number Publication date
CA2456322A1 (en) 2003-02-20
MXPA04001208A (en) 2004-07-08
AU2002319774B2 (en) 2005-04-21
EP1414418A1 (en) 2004-05-06
JP2005501067A (en) 2005-01-13
KR20040060917A (en) 2004-07-06
HUP0401195A2 (en) 2004-10-28
WO2003013479A1 (en) 2003-02-20
DE20220910U1 (en) 2004-08-05
HUP0401195A3 (en) 2006-11-28

Similar Documents

Publication Publication Date Title
BR0212019A (en) Dosage forms, methods for treating pain, methods of preparing a dosage form and methods for preventing abuse of a dosage form.
BR0212020A (en) Dosage forms, methods for preventing abuse of a dosage form, methods for preventing diversion of a dosage form, methods for treating pain and method of preparing a dosage form
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
BR0207024A (en) Fast-acting drug to treat sexual dysfunction
WO2002098370A3 (en) Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO2002058620A3 (en) Pharmaceutical compositions containing a cox-ii inhibitor and a muscle relaxant
BR0009647A (en) Docetaxel in combination with rhumab her2 for the treatment of cancers
BR9814923A (en) Method for treating alzheimer's disease
BRPI0415007A (en) method for treating, preventing, modifying or administering pain and pharmaceutical composition
EP1539234A4 (en) METHODS OF PREVENTING OR TREATING CELLULAR MALIGNITES BY ADMINISTERING CD2 ANTAGONISTS
PT1286671E (en) COMPOSITIONS FOR THE TREATMENT OF CANCER COLORRECTALQUE UNDERSTAND TALIDOMIDA AND IRINOTECAN
BR0013122A (en) Cyclobenzaprine for treatment of generalized anxiety disorder and cyclobenzaprine compositions
WO2004009015A3 (en) Combination therapy for the treatment of obesity
WO2004002999A8 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
BR0307508A (en) Compound, pharmaceutical composition, and methods of treating or preventing pain and inflammation and treating disease
SE0002754D0 (en) New pharmaceutical combination formulation and method of treatment with the combination
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
BRPI0412919A (en) combination of mglur2 antagonist and ache inhibitor for the treatment of chronic and / or acute neurological disorders
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
NO333189B1 (en) Use of buprenorphine for the preparation of a transdermal dosage form for the treatment of drug dependence, and seen extensively in such dosage forms.
PL368971A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
PT1102586E (en) USE OF GINKGO BILOBA EXTRACTS FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF AMIOTROPHIC LATERAL SCLEROSIS
BRPI0406634A (en) Use of an anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, non-oral pharmaceutical composition, and transdermal delivery device

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]